Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
    • Founders
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Investors & Media

Investors & Media

  • Overview
  • News
    • Email Alerts
    • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Company Info
    • Profile
    • Leadership
    • Contacts
    • Analyst Coverage
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Filings
    • Quarterly Reports
    • Proxy
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor & Media Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News

  • Email Alerts
  • Press Releases
Apr 24, 2019

Syros to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019

Apr 17, 2019

Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019

Apr 9, 2019

Syros Announces Closing of Concurrent Public Offerings

Apr 5, 2019

Syros Announces Pricing of $70 Million Concurrent Public Offerings

Apr 4, 2019

Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock

Apr 2, 2019

Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting

Mar 7, 2019

Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs

Mar 6, 2019

Syros to Participate in Upcoming Investor Conferences in March

Feb 28, 2019

Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019

Feb 27, 2019

Syros to Present New Preclinical Data on Its Selective CDK7 Inhibitors, SY-1365 and SY-5609, at AACR Annual Meeting

RSS
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...25
    © 2022 Syros Pharmaceuticals, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Sitemap
    twitter logo linkedin logo